Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lung Cancer
Screening for Lung Cancer
By
Dr. Edward Garon
Lung Cancer
,
WCLC 2016 – Lung Cancer
Videos
Dr. Edward Garon talks about the best approaches for screening patients for lung cancer.
Read Article
Smoking Cessation and Lung Cancer
By
Dr. Edward Garon
Lung Cancer
,
WCLC 2016 – Lung Cancer
Videos
Dr. Edward Garon discusses the importance of smoking cessation programs for patients diagnosed with lung cancer.
Read Article
Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment
By
Lisa A. Raedler, PhD, RPh
Lung Cancer
,
Value in Oncology
February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment
The rising cost of healthcare, including cancer care, is an established trend in the United States. In 2015, Americans spent $3.2 trillion (nearly $10,000 per person) on healthcare, including hospital inpatient and outpatient care, physicians’ services, and prescription drugs. The National Cancer Institute estimates that by 2020, the annual cost of healthcare for Americans with cancer will reach $156 billion; based on current trends, this means that cancer care will represent approximately 20% of the country’s annual healthcare expenditures.
Read Article
Common Concerns in Managing Patients with NSCLC
By
Dr. Edward Garon
Lung Cancer
,
WCLC 2016 – Lung Cancer
Videos
Dr Edward Garon provides an overview of the main concerns he has in managing patients with NSCLC, citing pseudoprogression as one of the biggest misconceptions.
Read Article
Improving Lung Cancer Screening
Lung Cancer
,
WCLC 2016 – Lung Cancer
Videos
Dr Suresh Ramalingam discusses the importance of screening for lung cancer and identifies the ideal patients to target for screening.
Read Article
Individualizing Treatment for Lung Cancer
Lung Cancer
,
WCLC 2016 – Lung Cancer
Videos
Dr Suresh Ramalingam examines the factors he considers when making treatment decisions for his patients.
Read Article
What's Ahead for Treating NSCLC
By
Dr. Edward Garon
Lung Cancer
,
WCLC 2016 – Lung Cancer
Videos
Although Dr Edward Garon feels the future of NSCLC is unclear, he cites how treatment has progressed over the years and wonders how immunotherapies and combination therapies will impact treatment.
Read Article
Adding Pembrolizumab to Chemotherapy as First-Line Treatment Significantly Improves Outcomes in Patients with Advanced NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Immunotherapy for advanced non–small-cell lung cancer (NSCLC) took a step toward first-line indication as results from a randomized clinical trial showed that patients who received pembrolizumab (Keytruda) plus chemotherapy had a significantly higher response rate compared with patients who received chemotherapy alone, reported Corey J. Langer, MD, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, at the 2016 European Society for Medical Oncology (ESMO) Congress. The clinical trial results (KEYNOTE-021) were also published in
Lancet Oncology
, and are available online.
Read Article
Immunotherapy with Atezolizumab Outperforms Chemotherapy in Previously Treated NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Immunotherapy competition in non–small-cell lung cancer (NSCLC) continued to heat up as atezolizumab (Tecentriq) improved overall survival (OS) versus docetaxel, according to results from the randomized, phase 3 OAK clinical trial reported at the 2016 European Society for Medical Oncology Congress by Fabrice Barlesi, MD, Professor of Medicine, Aix-Marseille University, France.
Read Article
Ceritinib, a Newer ALK Inhibitor, Improves Progression-Free Survival After Crizotinib Failure in NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with heavily pretreated
ALK
mutation and non–small-cell lung cancer (NSCLC) had significant improvement in progression-free survival (PFS) after receiving the next-generation ALK inhibitor ceritinib, according to results from the ASCEND-5 study reported at the 2016 European Society for Medical Oncology Congress by Giorgio Scagliotti, MD, Professor of Respiratory Medicine, University of Torino, Italy.
Read Article
Page 7 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma